Japanese

News Release

Investigator-Initiated Phase I Trial of CYT001 for unresectable advanced HCC will be started at Chiba University

CRECENT1 is a first clinical trial of CYT001 conducted by Chiba University. CYT001, a combination immunotherapy with HSP70 derived peptide, GPC3 derived peptide, LAG-3Ig (Eftilagimod alpha or IMP321) and Poly ICLC (Hiltonol), will be provided for CRESCENT1 trial under a research collaboration agreement between Chiba University and Cytlimic.
The recommended dose of CYT001 derived from YNP001, a First-in-Human study conducted at Yamaguchi University (PI: Hiroaki Nagano, MD, PhD, Professor and Chairman, Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University School of Medicine) has been adopted in CRECENT1 trial.
Cytlimic continues to advance the development of CYT001 through the clinical development collaborations with Chiba University (CRECENT1 trial) and Yamaguchi University (YNP01 and YCP02 studies).
CRESCENT1 trial : A Phase Ⅰ study of CYT001 in patients with unresectable advanced hepatocellular carcinoma (PI: Naoya Kato, MD, PhD, Professor, Department of Gastroenterology, Graduate School of Medicine, Chiba University)
YCP02 study : A phase I study of combination adjuvant immunotherapy with HSP70 derived peptide, GPC3 derived peptide, IMP321 and Hiltonol® for patients with resectable hepatocellular carcinoma (PI: Hiroaki Nagano, MD, PhD, Professor and Chairman, Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University School of Medicine, Co-Investigator: Shoichi Hazama, MD, PhD, Professor, Department of Translational Research and Developmental Therapeutics against Cancer, Yamaguchi University School of Medicine, Collaboration: Cytlimic Inc.) (UMIN000029991)
YNP01 study : A phase I study of combination immunotherapy with HSP70 derived peptide, GPC3 derived peptide, IMP321 and Hiltonol® for patients with advanced or metastatic solid cancer (PI: Hiroaki Nagano, MD, PhD, Professor and Chairman, Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University School of Medicine, Co-Investigator: Shoichi Hazama, MD, PhD, Professor, Department of Translational Research and Developmental Therapeutics against Cancer, Yamaguchi University School of Medicine, Collaboration: NEC Corporation, Cytlimic Inc.) (UMIN000020440)

PAGETOP